Gemcitabine-based chemotherapy remains an important treatment option for pancreatic ductal adenocarcinoma (PDAC), but the development of drug resistance significantly limits its clinical effectiveness. Elevated ribonucleotide reductase (RNR) activity, particularly involving its RRM1 and RRM2 subunits, is implicated in gemcitabine resistance by maintaining intracellular nucleotide pools and reducing the drug’s effectiveness. Researchers investigated sitagliptin, an established dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes, as a potential chemosensitizing agent.
Lupin Limited, a global pharmaceutical company headquartered in Mumbai, India, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. The approval represents an addition to the company’s generic pharmaceutical portfolio in the U.S. market and provides an opportunity to expand access to an established treatment option.
Zydus Lifesciences Limited announced on October 21, 2026, that the United States Food and Drug Administration (USFDA) had granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. The product is a generic equivalent of Climara Pro, a hormone therapy used in postmenopausal women. The approval expands Zydus’s portfolio of generic pharmaceutical products in the US market.
Biocon has announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Yesintek® (ustekinumab-kfce) as a single-dose prefilled autoinjector. Yesintek® is a biosimilar to Stelara® (ustekinumab), a biologic therapy used across several immune-mediated inflammatory diseases. The approval represents another advancement in Biocon’s expanding biosimilar portfolio and strengthens its presence in the U.S. immunology market.
Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has demonstrated renoprotective benefits in people with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, its potential association with nephrolithiasis has not been well characterized. A newly published real-world study in Scientific Reports evaluated the incidence of kidney stones among patients receiving finerenone compared with other commonly used CKD therapies.
